THE PRIMARY OBJECTIVE OF THIS PROJECT IS TO PROVIDE A NOVEL HEPARIN-LIKE MOLECULAR COMPONENT FOR SMALL BLOOD VESSEL PROSTHESES THAT WILL SIMULTANEOUSLY REDUCE OR PREVENT PERI- ANASTOMOTIC HYPERPLASIA AND REDUCE THROMBOGENICITY.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
4979
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Ernaco Inc
3740 Capulet Terrace, Silver Spring, MD, 20906
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MURIAL M LIPPMAN
PRINCIPAL INVESTIGATOR
(301) 598-5025
Business Contact:
() -
Research Institution:
n/a
Abstract
THE PRIMARY OBJECTIVE OF THIS PROJECT IS TO PROVIDE A NOVEL HEPARIN-LIKE MOLECULAR COMPONENT FOR SMALL BLOOD VESSEL PROSTHESES THAT WILL SIMULTANEOUSLY REDUCE OR PREVENT PERI- ANASTOMOTIC HYPERPLASIA AND REDUCE THROMBOGENICITY. THE IMMEDIATE SPECIFIC AIM IS TO OBTAIN A NEW SUPPLY OF THIS MATERIAL FROM ITS INVERTEBRATE SOURCE AND TO TEST ITS ANTIPROLIFERATIVE AND ANTICOAGULANT ACTIVITY. THE FIRST PHASE OF THE PROJECT WILL INVOLVE EXTRACTION AND ASSAY FOR ANTIPROLIFERATIVE ACTIVITIES ON AORTIC SMOOTH MUSCLE CELLS. SUBSEQUENT RESEARCH WILL INVOLVE TESTS ON HUMAN ENDOTHELIAL CELLS, BONDING TO THE STRUCTURAL POLYMER, AND LATER, IN COLLABORATION WITH CARDIOVASCULAR SURGEONS, TESTS FOR DEVELOPMENT OF THE PRODUCT FOR CLINICAL USE. THE COMMERCIALVALUE OF THE PRODUCT ARISES FROM THE EXPANDING MARKET FOR CARDIOVASCULAR PROSTHESES IN GENERAL AND FOR IMPROVED SMALL BLOOD VESSEL PROSTHESES IN PARTICULAR.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government